U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07817251) titled 'Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema' on Sept. 08.
Brief Summary: The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Study Start Date: Sept. 16
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus, Type 2
Intervention:
DRUG: CagriSema
CagriSema will be administered s.c. once weekly.
Recruitment Status: NOT_YET_RECRUITING
...